iShares US Pharmaceuticals ETF
178 hedge funds and large institutions have $550M invested in iShares US Pharmaceuticals ETF in 2025 Q4 according to their latest regulatory filings, with 45 funds opening new positions, 61 increasing their positions, 26 reducing their positions, and 14 closing their positions.
221% more first-time investments, than exits
New positions opened: 45 | Existing positions closed: 14
135% more repeat investments, than reductions
Existing positions increased: 61 | Existing positions reduced: 26
61% more capital invested
Capital invested by funds: $343M → $550M (+$207M)
19% more funds holding
Funds holding: 150 → 178 (+28)
6.52% more ownership
Funds ownership: 58.33% → 64.85% (+6.5%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FIA
Foundations Investment Advisors
Phoenix,
Arizona
|
+$51.3M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$26.3M |
| 3 |
Morgan Stanley
New York
|
+$22.7M |
| 4 |
ACM
Anfield Capital Management
Irvine,
California
|
+$9.41M |
| 5 |
JP Morgan Chase
New York
|
+$8.02M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$5.02M |
| 2 |
Fisher Asset Management
Camas,
Washington
|
-$4.84M |
| 3 |
Jane Street
New York
|
-$981K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$968K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$592K |
IHE Hedge Fund Activity: Q4 2025 in Review
178 of the 8,270 institutional investors tracked by Wall St. Rank reported a position in iShares US Pharmaceuticals ETF (IHE) for Q4 2025, worth a combined $550M — up 61% from $343M a quarter earlier.
Buyers outnumbered sellers: 45 funds opened new IHE positions and 14 closed out — a net gain of 31 holders — while 61 added to existing stakes and 26 trimmed.
The largest buyer was Foundations Investment Advisors, opening a new position worth an estimated $51.3M. The largest seller was Goldman Sachs, cutting an estimated $5.02M.
- 178 institutional investors held iShares US Pharmaceuticals ETF (IHE) as of Q4 2025, up from 150 in Q3 2025.
- Funds reported $550M of iShares US Pharmaceuticals ETF stock for Q4 2025, up 61% quarter-over-quarter.
- 45 funds opened new iShares US Pharmaceuticals ETF positions in Q4 2025 and 14 closed out, a net change of +31 holders.
- The largest iShares US Pharmaceuticals ETF buyer in Q4 2025 was Foundations Investment Advisors, an estimated $51.3M added.
- The largest iShares US Pharmaceuticals ETF seller in Q4 2025 was Goldman Sachs, an estimated $5.02M sold.
Based on aggregated 13F filings for Q4 2025.